Back
 
This activity already occurred and is no longer available.
A Review of New Guidelines and Treatment Options for Obesity
Obesity is a common diagnosis in the United States and affects more than one third of adults. As we learn more about obesity, there is an increasing interest in developing programs and treatments to both help prevent its development and lessen its negative effects. Obesity is defined by the World Health Organization as "abnormal or excessive fat accumulation that may impair health." Adults are commonly classified as being obese based on their body mass index (BMI). A BMI of greater than or equal to 25 kg/m2 is considered overweight and a BMI of greater than or equal to 30 kg/m2 is considered obese. Obesity is described as a national public health threat and is directly tied with an increased risk of morbidity and mortality. Pharmacists can play an important role in helping fight this threat.
Compounding for Otolaryngology

A Review of New Guidelines and Treatment Options for Obesity
Please read through the following information and click Continue.

ACPE Universal Program Number: 0207-0000-16-001-H01-P and 0207-0000-16-001-H01-T
Release Date: January 4, 2016
Expiration Date: January 4, 2019
Activity Type: Application-based

Statement of Need
Obesity is a common diagnosis in the United States and affects more than one third of adults. As we learn more about obesity, there is an increasing interest in developing programs and treatments to both help prevent its development and lessen its negative effects. Obesity is defined by the World Health Organization as "abnormal or excessive fat accumulation that may impair health." Adults are commonly classified as being obese based on their body mass index (BMI). A BMI of greater than or equal to 25 kg/m2 is considered overweight and a BMI of greater than or equal to 30 kg/m2 is considered obese. Obesity is described as a national public health threat and is directly tied with an increased risk of morbidity and mortality. Pharmacists can play an important role in helping fight this threat.

Pharmacists Learning Objectives
Upon successful completion of this activity, pharmacists should be better able to:

  1. Explain the key pharmacologic considerations for each Food and Drug Administration-approved chronic obesity medications.
  2. Describe recent guidelines on pharmacologic and nonpharmacologic management of obesity.
  3. Recommend clinically appropriate obesity medications on a patient by patient basis.

Pharmacy Technicians Learning Objectives
Upon successful completion of this activity, pharmacy technicians should be better able to:

  1. List the prescription drugs that are approved by FDA for treatment of chronic obesity.
  2. Describe recent guidelines on pharmacologic and nonpharmacologic management of obesity.
  3. Choose an appropriate course of action if a patient taking a prescription medication for the treatment of obesity appears to be experiencing an adverse event.

Any medications or treatment methods suggested in this activity should not be used by the practitioner without evaluation of their patient's condition(s) and possible contraindication(s) or danger(s) of use of any specific medication. This article contains a discussion of off-label uses that will be identified as such by the author.

Target Audience
The target audience for this activity is Pharmacists and Pharmacy Technicians.

Instructions for Participation
To receive a certificate of completion that indicates your eligibility for continuing education credit, you must:

  • Review the content of the activity.
  • Successfully complete the post-test (70% or higher).
  • You will have two (2) opportunities to successfully complete the activity.

Your statement of credit will be issued immediately upon successful completion of the post-test and submission of the evaluation.

Fee
There is no fee for this activity.

Accreditation
Pharmacists
ACPE logoNCPA is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity will provide 1.5 contact hours (0.15 CEUs) of continuing pharmacy education credit under the numbers 0207-0000-16-001-H01-P and 0207-0000-16-001-H01-T.

Faculty
Kylee Funk, PharmD, is a clinical faculty member of the University of Minnesota College of Pharmacy.

Disclosure Declaration
It is the policy of the National Community Pharmacists Association (NCPA) to ensure independence, balance, objectivity, scientific rigor, and integrity in all of their continuing education activities.

The authors, sponsor, and publisher of this continuing education activity have made all reasonable efforts to ensure that information contained herein is accurate in accordance with the latest available scientific knowledge at the time of accreditation of this continuing education program. Information regarding drugs (e.g., their administration, dosages, contraindications, adverse reactions, interactions, special warnings, precautions) and drug delivery systems are subject to change, however, and the reader is advised to check the manufacturer's package insert for information concerning recommended dosage and potential problems or cautions prior to dispensing or administering the drug or using the drug delivery systems.

Approval of credit for this continuing education activity does not imply endorsement by NCPA of any product or manufacturer identified.

Any medications or treatment methods suggested in this CE activity should not be used by the practitioner without evaluation of their patient's condition(s) and possible contraindication(s) or danger(s) of use of any specific medication.

Software Requirements

PC
Internet Explorer (Latest Version)
or Firefox (Latest Version)
*Adobe Acrobat Reader

MAC
Safari (Latest Version)
Firefox (Latest Version)
*Adobe Acrobat Reader

*REQUIRED TO VIEW PRINTABLE VERSION OF CE LESSON


Type:     Application-based CPE Activity
392 Registered Users